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Abstract
Background: Hypereosinophilia, defined by an absolute eosinophil count of more than 1500/mm3, is rarely
observed in patients treated for cancer, and rarely imputable to anti-cancer agents. Drug-induced hypereosinophilia
usually appears within a few weeks of the start of treatment and resolves after discontinuation of the medication.
We report here a first case of hypereosinophilia with digestive allergic reaction imputable to docetaxel in a woman
treated for breast cancer.
Case presentation: This patient, with a history of childhood atopic dermatitis and asthma, underwent surgery for
breast lobular carcinoma, followed with chemotherapy including 3 cycles of the FEC100 protocol and 3 cycles of
docetaxel. Ten days after the second cycle of docetaxel, she had abdominal pain with diarrhea, which increased
after the third cycle of docetaxel at the same dose. The blood eosinophil count increased up to 4685/mm3 at
day 92. All biological tests were normal, except elevated seric IgE. The systematic biopsies of the upper and lower
digestive tract showed diffuse edema of the lamina propria, lymphocytic infiltrate and CD117-expressing cells
both in the epithelium and in the lamina propria. Electron microscopy showed a large number of degranulating
mast cells, while the number of tissue eosinophils was small.
The blood eosinophil count decreased after day 96, three months after the last injection of docetaxel. After day 182,
the hypereosinophilia and symptoms resolved. This spontaneous evolution, the history of atopic dermatitis and
asthma, and the negativity of all biological tests performed led us to hypothesize a diagnosis of a systemic digestive
Type 1 drug-induced hypersensitivity reaction. Using two validated pharmacovigilance scales, we found that docetaxel
had the highest imputability score compared to the other drugs.
Conclusion: Recognition of allergic reactions imputable to docetaxel is important because it requires the drug to be
discontinued. In the difficult setting of anti-cancer treatment, if reintroduction of the drug is needed, a close collaboration
between oncologists, gastroenterologists and allergologists is required.
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Background
Hypereosinophilia, defined by an absolute eosinophil
count of more than 1500/mm3, is rarely observed in pa-
tients treated for cancer [1]. The main drugs responsible
for hyperesosinophilia are penicillins, cephalosporins,
sulfas, quinolones, and non-steroid anti-inflammatory
drugs [2], but hypereosinophilia is rarely imputable to
anti-cancer agents (see Additional file 1: Methods M1
for details on search strategy, and Additional file 2: Table
S1 for the results of the systematic literature search).
Drug-induced blood hypereosinophilia usually appears
within a 2 to 10 weeks of the start of treatment and re-
solves after discontinuation of the medication (Additional
file 2: Table S1).
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Blood hypereosinophilia is associated with potentially
lethal clinical complications, mainly cardiac, cutaneous,
neurologic or pulmonary [3].
We report here a first case of hypereosinophilia with
systemic digestive allergic reaction imputable to doce-
taxel in a woman treated for a localized breast cancer.
Case presentation
This 40-years-old Caucasian woman, with a history of
childhood atopic dermatitis and asthma, underwent sur-
gery for breast lobular carcinoma of 30 mm, histological
grade III, expressing estrogen and progesterone receptors,
with no lymph node involvement. In accordance with
French guidelines, she received post-surgery chemother-
apy including 3 cycles of the FEC100 protocol – 5Fluoro-
Uracile 500 mg/m2/cycle (Accord, France), epirubicin
100 mg/m2/cycle (Mylan, France) cyclophosphamid
500 mg/m2/cycle (Baxter, France) – and 3 cycles of doce-
taxel 100 mg/m2/cycle (Docetaxel Kabi © (ATC-Code
L01CD02), Fresenius, France).
Ten days after the second cycle of docetaxel, she had
abdominal pain with diarrhea (2–5 stools/day), which in-
creased after the third cycle of docetaxel at the same
dose. The eosinophil count was 2001/mm3 at day 60,
and 4685/mm3 at day 92 (Fig. 1).
Systematic biological tests and digestive biopsies were
performed at day 92. No parasitological, bacteriological,
virological, immunological or hematological cause was
found; only seric IgE were elevated (Additional file 3:
Table S2). The systematic biopsies of the upper and
lower digestive tract showed similarities in the gut and
colonic biopsies. All four biopsies had diffuse edema of
the lamina propria, lymphocytic infiltrate and CD117-
expressing cells both in the epithelium and in the lamina
propria (see Additional file 1: Methods and Fig. 2a). We
used electron microscopy, and anti-tryptase and anti-
eosinophil peroxidase antibodies to differentiate and
count mast cells and eosinophils in the two compart-
ments (see Additional file 1: Methods and Fig. 2b, c, and
Tables 1, 2). The diagnosis of eosinophilic gastro-
enteritis was excluded because of the small number of
tissue eosinophils [4]. Electron microscopy showed a
large number of degranulating mast cells. No sign of
thrombosis, necrosis or vascular-wall damage was found.
The blood eosinophil count decreased after day 96,
three months after the last injection of docetaxel. Des-
pite 4 months of hypereosinophilia, we did not detect
cardiac, respiratory, liver or renal complications.
After day 182, the hypereosinophilia and symptoms
resolved. This spontaneous evolution, the history of
atopic dermatitis and asthma, and the negativity of all
biological tests performed led us to hypothesize a
diagnosis of a drug-induced hypersensitivity reaction
(HSR). Using two validated pharmacovigilance scales,
we found that docetaxel had the highest imputability
score compared to the other drugs (Additional file 4:
Figure S1 and Table 3).
Docetaxel, a semi-synthetic taxoid that inhibits
depolymerization of microtubules, is currently ap-
proved for the treatment of breast, lung and prostate
cancers. The most frequent adverse effects of doce-
taxel are hematological (pancytopenia) and digestive.
Diarrhea is reported in 30 to 60 % of patients (Additional
file 5: Table S3), often associated with severe oral mucosi-
tis. These toxic lesions (Type A adverse drug reaction) are
predictable, dose-dependent reactions linked to prolonged
Fig. 1 Event time-line and blood eosinophil count curve. C1, C2, C3: first, second and third cycles of docetaxel
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Fig. 2 (See legend on next page.)
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Fig. 2 Characterization of cell infiltrates in the epithelium and lamina propria of the duodenum. Duodenal biopsies with CD117-expressing cells
(a), which include eosinophils expressing eosinophil peroxidase (EPO) and containing specific granules (b); and mast cells (M) expressing tryptase
and located in the lamina propria and epithelium (arrows, c). Mast cells in the lamina propria coexpress tryptase and chymase (d). Mast cells in
the epithelium (arrows) coexpress tryptase and carboxypeptidase A3 (e)
Table 1 Inflammatory cell counts in gut and colon
Digestive samples Epithelium
Lymphocytes Mast cells Eosinophils
Duodenum 10.2 ± 4.1 4.4 ± 0.8 2.4 ± 0.7
Jejunum 12.4 ± 3.1 2.3 ± 0.5 1.2 ± 0.5
Right colon 7.8 ± 1.2 2.5 ± 0.3 0.4 ± 0.1
Left colon 8.4 ± 0.9 3.2 ± 1.1 1.3 ± 0.4
Table 2 Inflammatory cell counts in gut and colon
Digestive samples Lamina propria
Lymphocytes Plasma cells Mast cells Eosinophils
Duodenum 66.3 ± 9.2 28.7 ± 5.1 12.3 ± 2.1 4.8 ± 0.9
Jejunum 70.8 ± 10.1 26.4 ± 4.5 9.6 ± 2.5 4.2 ± 1.1
Right colon 65.5 ± 7.5 27.9 ± 5.3 8.2 ± 1.6 3.5 ± 0.6
Left colon 58.0 ± 6.7 24.3 ± 3.9 9.5 ± 1.0 2.0 ± 0.3
Table 3 Drug imputability scores
Adverse Drug Reaction probability scale a French imputability score b
Drugs Score IS C S Intrinsic imputability
Docetaxel 7 2 3 3 16
Ondansetrone 4 2 1 2 12
Diosmectite −1 2 0 1 10
Paracetamol −1 2 0 1 10
Fluconazole −1 2 0 1 10
Racecadotril −1 2 0 1 10
Metoclopramide −1 2 0 1 10
Omeprazole −1 2 0 1 10
Phloroglucinol −1 2 0 1 10
Prednisone −1 2 0 1 10
IS Informativeness score, C chronology, S semiology
aNaranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–45
bArimone Y, Bidault I, Dutertre JP, et al. Updating the French method for the causality assessment of adverse drug reactions. Therapie 2013;68:69–76
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or daily exposure to the drug [5], whereas HSR under
docetaxel treatment (Type B immunologically-mediated
adverse drug reaction according to Gell-Coombs classifi-
cation, ref [5]) is dose-independent [6]. Severe HSR to do-
cetaxel is observed in 3 % to 7.7 % of patients (Additional
file 3: Table S2, and Reference [7] for review). Lethal drug-
induced HSR has been reported in 0.05 % of 36,983 pati
ents [8].
In the case of our patient who developed diarrhea and
severe hypereosinophilia after the second injection of
docetaxel, the two available pharmacovigilance scales
concluded to docetaxel imputability. Since our patient
had neither pancytopenia nor oral mucositis, and since
docetaxel had not been administered daily or for a pro-
longed period, we concluded that the diarrhea was not
related to a classic digestive toxicity but to Type B
immune-mediated adverse drug reaction. The digestive
symptoms occurred after the second injection of doce-
taxel, and the blood hypereosinophilia after the third in-
jection concomitantly with elevated seric IgE. The
digestive biopsies showed that the whole digestive tract
was involved, with edema, large numbers of mast cells,
and few eosinophils. Under electron microscopy, both
eosinophils and mast cells were degranulated. Overall,
these findings are in favor of a systemic digestive Type 1
hypersensitivity reaction.
Using specific antibodies (see Additional file 1: Methods),
we showed that mast cells and eosinophils were distributed
within the epithelium and the lamina propria. In bronchial
biopsies of mild to moderate TH2-high asthma associated
with blood eosinophilia [9], intra-epithelial mast cells co-
expressed tryptase and carboxypeptidase A3, whereas mast
cells of the lamina propria co-expressed tryptase and chy-
mase. We also found these differential enzymatic co-
expressions in epithelial and lamina propria mast cells in
the digestive biopsies of our patient (Fig. 2d, e). In asth-
matic and atopic patients, a similar immunoreactivity for
IL-3, IL-5 and GM-CSF has also been found in bronchial
and gut mucosa [10].
Conclusion
We here report a case of severe HSR with hypereosino-
philia imputable to docetaxel. While this condition is
rare, it is important to recognize it, since it requires the
drug to be discontinued. Since blood hypereosinophilia
over 1500/μL and lasting more than 1 month entails a
risk of major organ dysfunction [1, 11], including death
through cardiac failure [12], therapy discontinuation can
be recommended if these conditions are observed. In the
field of adverse reactions to anti-cancer drugs, this is
particularly relevant for docetaxel treatment, which can
be prolonged for several months in case of good re-
sponse for metastatic breast, lung or prostate cancers. If
reintroduction of this anti-cancer agent is needed, a
close collaboration between oncologists, gastroenterolo-
gists and allergologists is required.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor of this journal.
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